Alzheimer’s setback as promising drug shows no benefit in clinical trials

Disappointment as idalopirdine fails at trial to improve cognition and limit decline in patients with mild to moderate Alzheimer?s disease

https://www.theguardian.com/society/2018/jan/09/alzheimers-setback-as-promising-drug-shows-no-benefit-in-clinical-trials-idalopirdine

About Robert Zinn

Robert Zinn, M.D., Ph.D. is a medical doctor, physician, and web entrepreneur, who, for over 15 years was employed by academic and research institutions and focused his clinical practices on very specialized patient populations, such as those with rare genetic diseases or rare cancers. He shares his knowledge through his website, NutritionTheory.org

View all posts by Robert Zinn →